- Home
- SKLZ vs EPRX Comparison
SKLZ vs EPRX Comparison
Compare SKLZ & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKLZ
- EPRX
- Stock Information
- Founded
- SKLZ 2012
- EPRX 2011
- Country
- SKLZ United States
- EPRX Canada
- Employees
- SKLZ N/A
- EPRX N/A
- Industry
- SKLZ EDP Services
- EPRX
- Sector
- SKLZ Technology
- EPRX
- Exchange
- SKLZ Nasdaq
- EPRX NYSE
- Market Cap
- SKLZ 99.0M
- EPRX 85.5M
- IPO Year
- SKLZ N/A
- EPRX N/A
- Fundamental
- Price
- SKLZ $5.49
- EPRX $2.52
- Analyst Decision
- SKLZ Buy
- EPRX
- Analyst Count
- SKLZ 4
- EPRX 0
- Target Price
- SKLZ $10.67
- EPRX N/A
- AVG Volume (30 Days)
- SKLZ 66.9K
- EPRX 6.4K
- Earning Date
- SKLZ 11-06-2024
- EPRX 01-01-0001
- Dividend Yield
- SKLZ N/A
- EPRX N/A
- EPS Growth
- SKLZ N/A
- EPRX N/A
- EPS
- SKLZ N/A
- EPRX N/A
- Revenue
- SKLZ $118,060,000.00
- EPRX N/A
- Revenue This Year
- SKLZ N/A
- EPRX N/A
- Revenue Next Year
- SKLZ $7.32
- EPRX N/A
- P/E Ratio
- SKLZ N/A
- EPRX N/A
- Revenue Growth
- SKLZ N/A
- EPRX N/A
- 52 Week Low
- SKLZ $4.51
- EPRX $2.20
- 52 Week High
- SKLZ $7.48
- EPRX $3.50
- Technical
- Relative Strength Index (RSI)
- SKLZ 45.23
- EPRX N/A
- Support Level
- SKLZ $5.20
- EPRX N/A
- Resistance Level
- SKLZ $5.66
- EPRX N/A
- Average True Range (ATR)
- SKLZ 0.21
- EPRX 0.00
- MACD
- SKLZ 0.01
- EPRX 0.00
- Stochastic Oscillator
- SKLZ 40.85
- EPRX 0.00
About SKLZ Skillz Inc.
Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.